Karyopharm Therapeutics

345 articles about Karyopharm Therapeutics

• Karyopharm Therapeutics Announces Data Presentations at American Society of Hematology Annual Meeting

  11/8/2013

• Karyopharm Therapeutics Raises $109 Million in Upsized IPO, Begins Trading Today

  11/6/2013

• Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology on the Use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in Preclinical Models of Autoimmune Disease

  10/23/2013

• Karyopharm Therapeutics Enters IPO Queue, Plots Up to $80 Million Raise for Cancer Drug

  10/7/2013

• Karyopharm Therapeutics Announces Appointment of Garen Bohlin to Board of Directors

  10/3/2013

• Karyopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research Conferences

  8/8/2013

• Karyopharm Therapeutics Secures $19 Million in Series B Financing Extension

  8/1/2013

• Karyopharm Therapeutics Initiates a Phase 1b Food-Effect Clinical Trial With the Novel Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Sarcomas

  7/31/2013

• Karyopharm Therapeutics Announces Appointment of Paul Brannelly as Senior Vice President of Finance and Administration

  6/13/2013

• Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 American Society of Clinical Oncology Annual Meeting

  6/3/2013

• Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 European Hematology Association Congress

  5/29/2013

• Karyopharm Therapeutics Raises $48.2 Million in Series B Financing

  5/20/2013

• Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 American Society of Clinical Oncology Annual Meeting

  5/16/2013

• Karyopharm Therapeutics Gets $20.5 Million

  5/14/2013

• Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association for Cancer Research (AACR) Meeting

  3/26/2013

• Karyopharm Therapeutics Initiates Treatment of Patients With Acute Myeloid Leukemia (AML) in Phase 1 Trial With Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)

  1/17/2013

• Karyopharm Therapeutics Recognizes the Contributions of Co-Founder Ronald DePinho, MD

  11/1/2012

• Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in Cancer

  10/31/2012

• Karyopharm Therapeutics Announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)

  8/2/2012

• Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers

  7/25/2012